Revenue recognition change
beta
Filing comparison
Beta Bionics, Inc. changed its revenue recognition disclosure
Diluted net loss per share is computed by giving effect to all potentially dilutive securities outstanding during the period, unless their effect is anti-dilutive.
Evidence
- New language
- Diluted net loss per share is computed by giving effect to all potentially dilutive securities outstanding during the period, unless their effect is anti-dilutive., The amounts presented below represent potentially dilutive securities outstanding during the period, including both vested and unvested awards, that were excluded from the calculation of diluted net loss per share as their effect would have been anti-dilutive.
- Prior filed
- 2025-10-28
- Prior form
- 10-Q
- Similarity
- 0.516
- Source
- revenue recognition note comparison
- Threshold
- 0.6
- Why
- The revenue recognition policy disclosure changed materially from the previous comparable filing.
Language present now, absent from the prior filing:
- Diluted net loss per share is computed by giving effect to all potentially dilutive securities outstanding during the period, unless their effect is anti-dilutive.
- The amounts presented below represent potentially dilutive securities outstanding during the period, including both vested and unvested awards, that were excluded from the calculation of diluted net loss per share as their effect would have been anti-dilutive.